Genghis Capital, a leading investment bank in Kenya, has announced a partnership with EGM Securities, the online non-dealing forex broker, in a deal that expands Genghis services to a wider range of alternative asset classes including online currencies, commodities, global indices, precious metals and oil as well as high demand stocks.
Genghis Capital now has access to tech stocks such as Zoom, global banking stocks, pharmaceuticals, and biotech companies like Moderna and Gilead Sciences that are working towards a coronavirus vaccine.
Diverse asset classes
Mr Samwel Kiraka, CEO of EGM Securities, said his firm is part of a global group of companies with access to teams of specialists who can efficiently develop effective solutions for banks and brokerage houses.
EGM Securities is part of the Equiti Group of companies that has subsidiaries across the world such as Equiti Capital, regulated by Financial Conduct Authority (FCA) in the UK. “Our ambition is to be the premier provider of multi-asset products in Kenya, East Africa and the rest of Africa,” Mr Kiraka said. “We will achieve this by partnering with well-respected corporates such as Genghis.”
Head of Securities for Genghis Capital Kenneth Minjire said partnering with EGM Securities will allow its clients to trade for themselves in the global space and diversify their investments across various asset classes.
“We want to offer our clients additional options and exposure when it comes to investment vehicles. Since EGM Securities is regulated by the Capital Markets Authority of Kenya and Genghis has sophisticated clients willing to explore new asset classes for attractive returns, a partnership between our two companies is a natural fit,” Mr Kiraka said.
Genghis Capital has added some of the most sought after global stocks to its offering such as Facebook, Amazon and Alphabet, as well as numerous global airline and oil firms. It has recently added some key global hospitality brands like Mariott and Hyatt hotels and travel booking sites Booking.com and Expedia.
Responding to the vast flows of capital into medical research as the world looks to the pharmaceutical and biotech industries for a Coronavirus vaccine, Mr Kiraka said Genghis Capital has added popular pharmaceutical stocks such as Merck, Pfizer, GlaxoSmith, Biogen, Moderna and Gilead Sciences – whose Covid-19 treatment drug Remdesivir is now being used in hospitals.
Others are biotech upstarts that are regularly in the news like Amgen, Vertex and Regeneron, a leading science and technology company working on an experimental antibody treatment for Covid-19. “EGM Securities provides investors with the opportunity to be part of this modern medical gold rush and many other trading opportunities,” Mr Kiraka says.